ANIX

Anixa Biosciences, Inc. [ANIX] Stock Forecast

Q: What is Anixa Biosciences, Inc. stock symbol ?

Anixa Biosciences, Inc. is a US stock, located in San jose of Ca and trading under the symbol ANIX

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ANIX Stock Summary

Earnings have grown 481656.1% per last year.

EPS has been increasing for the past 3 years (Yearly statements)

Earnings are expected to fall -100% next year

ANIX has less than 1 year of cash runway

Top 10 Correlated ETFs

ANIX

Top 10 Correlated Stocks

ANIX

In the News

11:32 10 Jun 2023 ANIX

Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?

Here is how ANIXA BIOSCIENCES INC (ANIX) and Intuitive Surgical, Inc. (ISRG) have performed compared to their sector so far this year.

07:13 10 Jun 2023 ANIX

Anixa: I Am More Bullish After Efficacy Data For Its Triple-Negative Breast Cancer Vaccine

12:55 10 Jun 2023 ANIX

Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study Data

Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.

10:32 10 Jun 2023 ANIX

What Makes ANIXA BIOSCIENCES INC (ANIX) a Good Fit for "Trend Investing"

ANIXA BIOSCIENCES INC (ANIX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

08:30 10 Jun 2023 ANIX

Anixa Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SAN JOSE, Calif. , Aug. 31, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present a company update at the H.C.

01:38 10 Jun 2023 ANIX

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

Anixa Biosciences has different very interesting programs ongoing, one of which is a breast cancer vaccine trial with a first partial readout at ASCO in the beginning of June. While the biotech sector has been suffering large losses over the past month, Anixa Biosciences shares have moved up remarkably.

11:18 10 Jun 2023 ANIX

Has Anixa Biosciences (ANIX) Outpaced Other Medical Stocks This Year?

Here is how ANIXA BIOSCIENCES INC (ANIX) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.

09:05 10 Jun 2023 ANIX

Anixa (ANIX) COVID Compounds Prove Effective Against Omicron

Anixa Biosciences' (ANIX) potential COVID-19 compounds show effectiveness against the Omicron variant of COVID-19.

08:30 10 Jun 2023 ANIX

Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy

SAN JOSE, Calif., Oct. 1, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa's novel Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology, known as its Chimeric Endocrine Receptor T-cell, or CER-T approach, or more specifically, "Follicle Stimulating Hormone Receptor-Mediated CAR-T technology," which has been licensed from The Wistar Institute and is being developed in partnership with Moffitt Cancer Center.

08:31 10 Jun 2023 ANIX

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming Emerging Immunotherapeutics for Ovarian Cancer Symposium

SAN JOSE, Calif., Sept. 14, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the inventor of its ovarian cancer CAR-T technology, Dr. José Conejo-Garcia, Chair of the Immunology Department at Moffitt Cancer Center, will be presenting at the Antibody Society and Ovarian Cancer Research Alliance's Emerging Immunotherapeutics for Ovarian Cancer Symposium on September 23, 2021.

ANIX Financial details

Company Rating

Buy

Market Cap

105.76M

Income

-11.76M

Revenue

2.47B

Book val./share

0.9

Cash/share

0.9

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

10 Jun 2022

P/E

-8.99

Forward P/E

PEG

6.45

P/S

0.04

P/B

3.81

P/C

3.83

P/FCF

-14.52

Quick Ratio

22.6

Current Ratio

22.81

Debt / Equity

0.01

LT Debt / Equity

0.01

EPS (TTM)

-0.39

EPS next Y

EPS next Q

EPS this Y

-2.22%

EPS next Y

EPS next 5Y

EPS last 5Y

-11.92%

Revenue last 5Y

366.92%

Revenue Q/Q

EPS Q/Q

-37.64%

SMA20

-12.27%

SMA50

-22.04%

SMA100

-24.83%

Inst Own

100%

Inst Trans

88.03%

ROA

-42%

ROE

-39%

ROC

-0.46%

Gross Margin

100%

Oper. Margin

-1%

Profit Margin

Payout

Shs Outstand

30.92M

Shs Float

29.52M

Target Price

52W Range

2.77-6.45

52W High

-42.61%

52W Low

+72.19%

RSI

44.55

Rel Volume

0.18

Avg Volume

98.38K

Volume

17.91K

Perf Week

12.54%

Perf Month

-15.8%

Perf Quarter

-17.02%

Perf Half Y

-29.58%

Beta

0.95109

Volatility

0.12%, 0.28%

Prev Close

-1.61%

Price

3.4437

Change

-0.76%

ANIX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-10-31

Metric	2018-10-31	2019-10-31	2020-10-31	2021-10-31	2022-10-31
Revenue per share	0.06	0.01	0	0.02	81.29
Net income per share	-0.83	-0.63	-0.46	-0.45	-0.44
Operating cash flow per share	-0.24	-0.24	-0.28	-0.17	-0.21
Free cash flow per share	-0.24	-0.25	-0.28	-0.17	-0.21
Cash per share	0.29	0.3	0.41	1.25	0.98
Book value per share	0.31	0.26	0.39	1.24	0.96
Tangible book value per share	0.25	0.24	0.37	1.22	0.93
Share holders equity per share	0.31	0.26	0.39	1.24	0.96
Interest debt per share	0	0	0	0.01	0.01
Market cap	71.38M	76.59M	45.79M	145.47M	170.09M
Enterprise value	68.32M	73.09M	39.43M	116.6M	157.96M
P/E ratio	-4.9	-6.17	-4.45	-11.24	-12.61
Price to sales ratio	64.16	306.35	0	283.84	0.07
POCF ratio	-16.7	-16.15	-7.41	-29.47	-26.2
PFCF ratio	-16.55	-15.58	-7.4	-29.47	-26.2
P/B Ratio	13.13	14.63	5.23	4.1	5.86
PTB ratio	13.13	14.63	5.23	4.1	5.86
EV to sales	61.41	292.38	0	227.51	0.06
Enterprise value over EBITDA	-5.13	-6.9	-4.05	-8.91	-11.42
EV to operating cash flow	-15.99	-15.42	-6.38	-23.62	-24.33
EV to free cash flow	-15.85	-14.87	-6.37	-23.62	-24.33
Earnings yield	-0.2	-0.16	-0.22	-0.09	-0.08
Free cash flow yield	-0.06	-0.06	-0.14	-0.03	-0.04
Debt to equity	0	0	0.01	0.01	0.01
Debt to assets	0	0	0.01	0.01	0.01
Net debt to EBITDA	0.23	0.33	0.65	2.21	0.88
Current ratio	4.38	4.11	7.88	28.34	14.83
Interest coverage	0	0	0	0	-133.41
Income quality	0.3	0.4	0.61	0.38	0.47
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	6.21	22.65	0	13.8	0
Research and developement to revenue	6.12	21.89	0	12.08	0
Intangibles to total assets	0.13	0	0	0	0
Capex to operating cash flow	0.01	0.04	0	0	0
Capex to revenue	-0.03	-0.7	0	0	0
Capex to depreciation	-0.11	-0.38	-0.18	0	0
Stock based compensation to revenue	8	22.85	0	15.72	0
Graham number	2.4	1.93	2.03	3.55	3.09
ROIC	57.2	9.45	2.81	0.58	-2.5
Return on tangible assets	-2.6	-1.97	-1.09	-0.36	-0.44
Graham Net	0.22	0.22	0.35	1.2	0.9
Working capital	4.27M	4.61M	8.18M	34.73M	28.16M
Tangible asset value	4.35M	4.81M	8.26M	34.77M	28.2M
Net current asset value	4.27M	4.61M	8.18M	34.51M	27.99M
Invested capital	0	0	0.01	0.01	0.01
Average receivables	0	33.26K	34.38K	1.12K	0
Average payables	531.17K	583.91K	409.09K	184.28K	200.6K
Average inventory	0	0	0	0	0
Days sales outstanding	0	97.13	0	0	0
Days payables outstanding	276.46	1.29K	0	129.12	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	3.76	0	0	0
Payables turnover	1.32	0.28	0	2.83	0
Inventory turnover	0	0	0	0	0
ROE	-2.68	-2.37	-1.17	-0.37	-0.46
Capex per share	0	-0.01	0	0	0

Quarterly Fundamentals Overview

Last date of statement is 2023-01-31 for Q1

Metric	2022-01-31	2022-04-30	2022-07-31	2022-10-31	2023-01-31
Revenue per share	0	0	0	81.29	0
Net income per share	-0.13	-0.12	-0.09	-0.11	-0.07
Operating cash flow per share	-0.04	-0.08	-0.05	-0.05	-0.06
Free cash flow per share	-0.04	-0.08	-0.05	-0.05	-0.06
Cash per share	1.15	1.07	1.04	0.98	0.9
Book value per share	1.13	1.07	1.04	0.96	0.9
Tangible book value per share	1.1	1.04	1.01	0.93	0.87
Share holders equity per share	1.13	1.07	1.04	0.96	0.9
Interest debt per share	0.01	0.01	0.01	0.01	0.01
Market cap	98.81M	97.99M	118.15M	170.09M	135.12M
Enterprise value	69.28M	70.5M	94.13M	157.96M	125.54M
P/E ratio	-6.45	-6.92	-10.93	-12.52	-15.93
Price to sales ratio	0	0	0	0.07	0
POCF ratio	-82.55	-42.5	-84.63	-106.78	-67.97
PFCF ratio	-82.55	-42.5	-84.63	-106.78	-67.97
P/B Ratio	2.91	3.05	3.73	5.86	4.86
PTB ratio	2.91	3.05	3.73	5.86	4.86
EV to sales	0	0	0	0.06	0
Enterprise value over EBITDA	-17.9	-19.7	-33.77	-43.9	-49.33
EV to operating cash flow	-57.88	-30.57	-67.43	-99.16	-63.15
EV to free cash flow	-57.88	-30.57	-67.43	-99.16	-63.15
Earnings yield	-0.04	-0.04	-0.02	-0.02	-0.02
Free cash flow yield	-0.01	-0.02	-0.01	-0.01	-0.01
Debt to equity	0.01	0.01	0.01	0.01	0.01
Debt to assets	0.01	0.01	0.01	0.01	0.01
Net debt to EBITDA	7.63	7.68	8.62	3.37	3.76
Current ratio	19.58	27.39	22.01	14.83	22.81
Interest coverage	-3.88K	-3.59K	-127.14	-45.11	-12.65
Income quality	0.31	0.64	0.5	0.45	0.84
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	1.8	1.68	1.44	1.55	1.18
ROIC	0.15	0.16	0.17	-0.64	-0.27
Return on tangible assets	-0.11	-0.11	-0.08	-0.11	-0.07
Graham Net	1.08	1.02	0.99	0.9	0.85
Working capital	33.21M	31.37M	30.87M	28.16M	26.87M
Tangible asset value	33.24M	31.41M	30.91M	28.2M	26.91M
Net current asset value	33M	31.17M	30.68M	27.99M	26.71M
Invested capital	0.01	0.01	0.01	0.01	0.01
Average receivables	0	0	0	0	73.5K
Average payables	320.1K	298.5K	160K	246K	187.5K
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.11	-0.11	-0.09	-0.12	-0.08
Capex per share	0	0	0	0	0

ANIX Frequently Asked Questions

What is Anixa Biosciences, Inc. stock symbol ?

Anixa Biosciences, Inc. is a US stock , located in San jose of Ca and trading under the symbol ANIX

Is Anixa Biosciences, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $8. The lowest prediction is $8 and the highest is $8

What is ANIX stock prediction ?

What is Anixa Biosciences, Inc. stock quote today ?

Anixa Biosciences, Inc. stock price is $3.4437 today.

Is Anixa Biosciences, Inc. stock public?

Yes, Anixa Biosciences, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 98.38K
Market Capitalization 105.76M
Employee 4
CEO Dr. Amit Kumar Ph.D.
Headquarters San Jose,CA,US
IPO Date 1983-10-07
Website https://www.anixa.com

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.